Phase II Study With Cabozantinib in Patients With RET Positive NSCLC (CRETA) | EXEL Message Board Posts

EXEL   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  22945 of 23128  at  10/18/2019 8:44:03 PM  by

Pacific


Phase II Study With Cabozantinib in Patients With RET Positive NSCLC (CRETA)

https://clinicaltrials.gov/ct2/show/NCT04131543

ClinicalTrials.gov Identifier: NCT04131543
Recruitment Status : Recruiting
First Posted : October 18, 2019
Last Update Posted : October 18, 2019

Sponsor: University of Bologna
Collaborators: AOU S.Orsola Malpighi-Unit of Oncologic Molecular and Transplantations Pathology
Bioikos Ambiente Srl
Ipsen
Mipharm SpA
Information provided by (Responsible Party):
Andrea Ardizzoni, University of Bologna

Brief Summary:
This study is aimed to explore the antitumor activity, safety and efficacy profile of cabozantinib in pretreated, advanced RET-rearranged non-small cell lung cancer patients

Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 25 participants
Intervention Model: Single Group Assignment
Intervention Model Description: Single-arm, ope label clinical trial
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: "Phase II Study to Evaluate the Activity and Safety of Cabozantinib in Pretreated, Advanced RET-rearranged Non-small Cell Lung Cancer Patients: CRETA Trial"
Actual Study Start Date: August 7, 2019
Estimated Primary Completion Date: August 7, 2020
Estimated Study Completion Date: August 7, 2022



     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 5     Views: 300
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
22946 Re: Phase II Study With Cabozantinib in Patients With RET Positive NSCLC (CRETA) wilderguide 3 10/18/2019 11:22:46 PM


About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...